NO20052335L - Dispergerbare deferacirox-tabletter - Google Patents

Dispergerbare deferacirox-tabletter

Info

Publication number
NO20052335L
NO20052335L NO20052335A NO20052335A NO20052335L NO 20052335 L NO20052335 L NO 20052335L NO 20052335 A NO20052335 A NO 20052335A NO 20052335 A NO20052335 A NO 20052335A NO 20052335 L NO20052335 L NO 20052335L
Authority
NO
Norway
Prior art keywords
dispersible
tablets
deferacirox
triazol
hydroxyphenyl
Prior art date
Application number
NO20052335A
Other languages
English (en)
Other versions
NO20052335D0 (no
NO336958B1 (no
Inventor
Karine Defez
Jean-Pierre Casserie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9945957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052335(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20052335D0 publication Critical patent/NO20052335D0/no
Publication of NO20052335L publication Critical patent/NO20052335L/no
Publication of NO336958B1 publication Critical patent/NO336958B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

Dispergerbare tabletter innbefattende som aktiv bestanddel 4-[3,5-bis(2-hydroksyfenyl)[1,2,4]triazol-1-yl]benzosyre eller et farmasøytisk akseptabelt salt derav på fra 5 til 40 vekt-% basert på den totale tablettens vekt.
NO20052335A 2002-10-15 2005-05-12 Dispergerbare deferasirox-tabletter og fremgangsmåte for fremstilling derav NO336958B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223978.8A GB0223978D0 (en) 2002-10-15 2002-10-15 Organic compound
PCT/EP2003/011351 WO2004035026A1 (en) 2002-10-15 2003-10-14 Deferacirox dispersible tablets

Publications (3)

Publication Number Publication Date
NO20052335D0 NO20052335D0 (no) 2005-05-12
NO20052335L true NO20052335L (no) 2005-07-15
NO336958B1 NO336958B1 (no) 2015-12-07

Family

ID=9945957

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052335A NO336958B1 (no) 2002-10-15 2005-05-12 Dispergerbare deferasirox-tabletter og fremgangsmåte for fremstilling derav

Country Status (33)

Country Link
US (5) US20060110446A1 (no)
EP (1) EP1556013B8 (no)
JP (4) JP2006504748A (no)
KR (1) KR100765580B1 (no)
CN (2) CN101912391A (no)
AR (1) AR041609A1 (no)
AT (1) ATE431138T1 (no)
AU (1) AU2003278078B2 (no)
BR (1) BR0315264A (no)
CA (1) CA2501659C (no)
CY (1) CY1109902T1 (no)
DE (1) DE60327646D1 (no)
DK (1) DK1556013T3 (no)
EC (1) ECSP055733A (no)
EG (1) EG25453A (no)
ES (1) ES2326167T3 (no)
GB (1) GB0223978D0 (no)
IL (1) IL167709A (no)
JO (1) JO2700B1 (no)
MX (1) MXPA05003999A (no)
MY (1) MY140999A (no)
NO (1) NO336958B1 (no)
NZ (1) NZ539354A (no)
PA (1) PA8586501A1 (no)
PE (1) PE20040496A1 (no)
PL (1) PL213325B1 (no)
PT (1) PT1556013E (no)
RU (1) RU2338532C2 (no)
SI (1) SI1556013T1 (no)
TN (1) TNSN05109A1 (no)
TW (1) TWI339657B (no)
WO (1) WO2004035026A1 (no)
ZA (1) ZA200502488B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
NZ567155A (en) * 2005-10-19 2010-06-25 Novartis Ag Dispersible tablets comprising deferasirox
JP2009536180A (ja) 2006-05-09 2009-10-08 ノバルティス アクチエンゲゼルシャフト 鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
TWI448285B (zh) 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
EP1994930A1 (en) 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
JP2012520878A (ja) 2009-03-19 2012-09-10 ロサンゼルス ビオメドイカル リサーチ インストイトウテ アト ハルボル‐ユーシーエルエー メドイカル センテル ムコール菌症、及びその他の真菌疾患の治療のためのワクチン組成物、及び方法
CA2805568A1 (en) * 2010-07-08 2012-01-12 Ratiopharm Gmbh Oral dosage form of deferasirox
PE20140166A1 (es) 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
WO2012096183A1 (ja) 2011-01-14 2012-07-19 株式会社ダステック 高分子鉄キレート剤
EP2916870A1 (en) 2012-11-12 2015-09-16 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferipone
HUE036921T2 (hu) 2013-03-08 2018-08-28 Novartis Ag Orális deferasirox készítmények
RU2015149544A (ru) * 2013-05-10 2017-06-16 Сипла Лимитед Низкодозовая фармацевтическая композиция
CN103735519A (zh) * 2014-01-10 2014-04-23 无锡万全医药技术有限公司 一种地拉罗司颗粒剂及其制备方法
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
KR101695970B1 (ko) 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
EP3248594A1 (en) * 2016-05-25 2017-11-29 ratiopharm GmbH Tablet for multiple oral applications
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
EP3675832A1 (en) 2017-09-01 2020-07-08 Jordan Sweden Medical and Sterilization Company Fast self dispersible dosage forms of deferasirox
WO2019108157A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation in a dispersible form comprising deferasirox
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
TR201722910A2 (tr) * 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
YU183988A (en) * 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
UA37214C2 (uk) * 1991-01-30 2001-05-15 Дзе Веллкам Фаундейшн Лімітед Таблетки, що диспергуються у воді, та спосіб їх виготовлення
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
DE4412117A1 (de) * 1994-04-08 1995-10-12 Fette Wilhelm Gmbh Verfahren und Vorrichtung zum Aufbringen von pulverförmigem Schmier- oder Trennmittel auf die Preßwerkzeuge in Tablettiermaschinen
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
WO1999052491A1 (en) * 1998-04-08 1999-10-21 Kyowa Hakko Kogyo Co., Ltd. Tablet manufacturing method and tablet
JP2000063269A (ja) * 1998-08-20 2000-02-29 Taiho Yakuhin Kogyo Kk 固形製剤
JP2000086503A (ja) * 1998-09-07 2000-03-28 Pola Chem Ind Inc 錠剤医薬組成物
KR100720877B1 (ko) * 1998-12-28 2007-05-22 다케다 야쿠힌 고교 가부시키가이샤 비타민 제제
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
JP2002033764A (ja) * 2000-07-14 2002-01-31 Fujitsu Ltd 通信サービス提供システム、並びに通信サービス提供システムにおいて使用される移動端末装置、アドレスサーバ装置、およびルータ装置
JP4886107B2 (ja) * 2000-10-13 2012-02-29 サンスター株式会社 歯周病予防用口腔内溶解錠

Also Published As

Publication number Publication date
MY140999A (en) 2010-02-12
CY1109902T1 (el) 2014-09-10
JP2016094435A (ja) 2016-05-26
NO20052335D0 (no) 2005-05-12
MXPA05003999A (es) 2005-06-22
RU2005114904A (ru) 2006-01-27
PL375166A1 (en) 2005-11-28
PT1556013E (pt) 2009-08-10
WO2004035026A1 (en) 2004-04-29
CN101912391A (zh) 2010-12-15
EG25453A (en) 2012-01-19
TW200410949A (en) 2004-07-01
AU2003278078A1 (en) 2004-05-04
US20120196909A1 (en) 2012-08-02
ZA200502488B (en) 2005-11-30
AR041609A1 (es) 2005-05-26
JP2014088417A (ja) 2014-05-15
JP2010031022A (ja) 2010-02-12
ES2326167T3 (es) 2009-10-02
GB0223978D0 (en) 2002-11-20
CA2501659A1 (en) 2004-04-29
KR100765580B1 (ko) 2007-10-09
KR20050071578A (ko) 2005-07-07
US20110046193A1 (en) 2011-02-24
JP2006504748A (ja) 2006-02-09
US20060110446A1 (en) 2006-05-25
US20160175255A1 (en) 2016-06-23
NZ539354A (en) 2007-04-27
DE60327646D1 (de) 2009-06-25
SI1556013T1 (sl) 2009-10-31
AU2003278078B2 (en) 2007-08-02
TWI339657B (en) 2011-04-01
EP1556013B8 (en) 2010-03-03
ECSP055733A (es) 2005-07-06
EP1556013B1 (en) 2009-05-13
US20110319457A1 (en) 2011-12-29
PL213325B1 (pl) 2013-02-28
IL167709A (en) 2015-05-31
PE20040496A1 (es) 2004-09-20
HK1081101A1 (en) 2006-05-12
RU2338532C2 (ru) 2008-11-20
ATE431138T1 (de) 2009-05-15
BR0315264A (pt) 2005-08-23
TNSN05109A1 (en) 2007-05-14
JO2700B1 (en) 2013-03-03
CA2501659C (en) 2011-08-23
JP5908505B2 (ja) 2016-04-26
NO336958B1 (no) 2015-12-07
CN1705471A (zh) 2005-12-07
EP1556013A1 (en) 2005-07-27
DK1556013T3 (da) 2009-08-17
PA8586501A1 (es) 2005-02-04

Similar Documents

Publication Publication Date Title
MY140999A (en) Dispersible tablets comprising a benzoic acid derivative
NO20045072L (no) Tablett med hoyt medikamentinnhold
TW200603841A (en) Dispersible tablets comprising a benzoic acid derivative
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
NO20072939L (no) Makroloner - aminosubstituerte kinoloner
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
NO20100569L (no) Farmasoytiske formuleringer og anvendelse derav i forebyggelsen av slag, diabetes og/eller kongestivt hjertesvikt
EP1392639A4 (en) Pyruvate derivatives
AR070051A2 (es) Una preparacion farmaceutica para la cura del sindrome de xeroftalmia
EA200702198A1 (ru) Фармацевтические составы
NO20054868L (no) CaSr antagonist
NO20010833L (no) Orale mukoadhesive sammensetninger inneholdende gastrointestinale aktive bestanddeler
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
NO991761L (no) Nye piperidin-kotokarbonsyre-derivater, deres fremstilling og anvendelse
NO20053398D0 (no) Farmasoytiske preparater av sertaconazol for vaginal anvendelse.
NO20040881L (no) Orale antidiabetes midler.
JP2000159790A5 (no)
WO2003080125A3 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
DE502005006070D1 (de) Kosmetische formulierung auf mikroemulsionsbasis enthaltend mandelsäure
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes

Legal Events

Date Code Title Description
MK1K Patent expired